Navigation Links
Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
Date:5/18/2011

PARIS and OSAKA, Japan, May 18, 2011 /PRNewswire/ -- Cellectis bioresearch, a subsidiary of Cellectis (Alternext: ALCLS) and genome customization specialist, has appointed Wako Pure Chemical Industries as its distributor in Japan for the Company's broad portfolio of research products and services, including the recently launched TALEN(1) Access™. Wako Pure Chemical Industries is a leading distributor of research products in Japan.

"In February 2011, we launched our revolutionary rapid, custom-designed TALEN service that enables access to genome customization tools to a large audience of life science researchers, due to its affordable price,” said Luc Selig, VP Sales & Marketing at Cellectis bioresearch. "We are now targeting rapid global distribution and Japan is a major player in life science research. Wako will allow us to enter this important market effectively, thanks to its key position."

Cellectis bioresearch's current portfolio includes more than 200 product references that address the genome customization requirements of life science researchers. In the last 12 months, Cellectis bioresearch has deployed its own sales force in Europe and the USA and has appointed agents and distributors in Canada and India. Online purchase is also available through the Cellectis bioresearch website.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.

The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at www.cellectis.com  

Follow Cellectis on Twitter at www.twitter.com/cellectis

About Wako Pure Chemical Industries, Ltd.

Wako Pure Chemical Industries, Ltd., which is headquartered at Osaka (Japan) is the Japan's largest manufacture of laboratory chemical, specialty chemicals, and diagnostic reagents. Wako was founded in 1922 and currently has 1,440 employees, locating offices in all over in Japan, Europe and US. Wako contribute to the development of science and technology and create a prosperous future.

For further information, please go to: http://www.wako-chem.co.jp/english/

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) TALEN: Transcription Activator-Like Effector Nucleases


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells
2. Cellectis Receives Payment for License to Homologous Recombination Patents
3. Cellectis Publishes 2010 Financial Results
4. Cellectis and the Etablissement Francais du Sang Launch StemRed, a Program to Produce Red Blood Cells From Stem Cells
5. Cellectis bioresearch First to Launch Revolutionary Custom TAL Nuclease Service
6. Cellectis Meganuclease Technology Used to Efficiently Prevent Viral Infection
7. Cellectis bioresearch Announces the First TGCA Winner
8. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
9. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
10. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
11. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):